Lancet Oncology research says 12% of new cancer cases are infection-linked
Roughly 12 percent of new cancer cases reported globally in 2024 can be traced back to 12 underlying infections, meaning approximately 2.3 million cancer illnesses worldwide could potentially have been prevented, according to research published in The Lancet Oncology.
-
Key Clinical Takeaways:
- Five specific infections account for more than 2.2 million of the estimated 2.3 million infection-attributable cancer cases recorded in the global study.
- The common stomach infection Helicobacter pylori and the sexually transmitted human papillomavirus drive about 1.5 million of these diagnoses.
- Low- and middle-income countries bear 77 percent of the total infection-related cancer burden, driven by disparities in resource access.
Global Cancer Burden Linked to Preventable Pathogens
While the vast majority of cancer diagnoses stem from other biological drivers, infections remain a significant, treatable, and entirely preventable catalyst for roughly 1 in 8 cancer cases worldwide. Five primary pathogens account for the vast majority of this burden. Helicobacter pylori accounts for approximately 760,000 cases, representing 4 percent of new cancer diagnoses globally through its association with gastric cancers. Human papillomavirus accounts for roughly 750,000 cases, or another 4 percent of new diagnoses, predominantly through cervical cancer.
Hepatitis B virus drives an estimated 360,000 liver cancer cases, or 2 percent of new diagnoses. Epstein-Barr virus is linked to roughly 260,000 head and neck cancer cases, or 1 percent of new diagnoses. Hepatitis C virus accounts for approximately 160,000 liver cancer cases, representing just under 1 percent of new diagnoses globally. Additional pathogens identified in the study include HIV, Kaposi’s sarcoma-associated herpesvirus, Schistosoma haematobium, Human T-cell lymphotropic virus type 1, Opisthorchis viverrini, Clonorchis sinensis, and Merkel cell polyomavirus.
Low-Income Countries Bear Most Infection-Related Cancer Cases
Geographic inequality shapes the distribution of infection-driven malignancies. The study found that 77 percent of all infection-related cancer cases occur in low- and middle-income countries. Eastern Asia, Sub-Saharan Africa, and Southeast Asia experience the largest share of this burden. Cancer registries in these lower-income regions are frequently less complete, complicating precise measurement of the global infection-related cancer burden. The estimates rely on global cancer data and prior research rather than tracking every individual cancer case, leaving room for unrecorded infections that lack sufficient current evidence to establish a definitive cancer link.
Vaccination and Treatment Deficits in High-Burden Areas
Proven medical interventions exist to prevent and treat these specific pathogens, yet availability varies sharply by region. Areas carrying the highest cancer burden often lack the infrastructure required to track, prevent, and control infections. Centers for Disease Control and Prevention data show that vaccination against human papillomavirus yields substantial protective effects. Within 12 years of the introduction of the Gardasil vaccine in the United States, targeted HPV infections dropped 88 percent among females aged 14 to 19 and 81 percent among females aged 20 to 24. Concurrently, cervical precancer rates dropped 50 percent in 18- to 20-year-olds and 36 percent in 21- to 24-year-olds.
Hepatitis B vaccination is recommended by the CDC for infants, children, and adults aged 19 to 59, alongside adults aged 60 and older who face high infection risks. Routine screening and antibiotic treatment for Helicobacter pylori reduce microbial spread and lower the risk of malignant progression. Similar testing and treatment protocols for hepatitis B, hepatitis C, and HIV stop transmission and prevent infections from advancing to chronic states that elevate cancer risk. Additional risk-reduction strategies include safer injection practices, condom distribution, pre-exposure prophylaxis use, and screening for precancerous cervical and anal lesions.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.